obesity drug news today october 21 2025 glp-1 Receptor Agonists – From Evolution to Revolution GLP-1 drug coverage for obesity

Chronic treatment with P5 and Ex4 significantly reduced ectopic lipid deposition in the liver as indicated by a decrease in the number of lipid droplets (Fig

Weight loss is a personal journey and can be impacted by several factors, including your starting weight, lifestyle changes, and side effects

10.1172/JCI116186 129 NESINA (2013)

But enforcing this traditional doctrine has already failed in the United States, which is why 50% of Americans are projected to become obese by 2030

The road ahead, however, comes with challenges pricing, insurance access, and long-term safety will determine how equitable this revolution truly becomes

For clinics developing truly integrated medical weight loss programs, a once-weekly GLP-1 analog called ecnoglutide is emerging as the most advanced biased-signaling option yet